Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. Abs 0974 #ACR22 @RheumNow
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers - ACR Meeting Abstracts
